Tempus AI (TEM), announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based ...
David R. Epstein, a director at Tempus AI , Inc. (NASDAQ:TEM), recently sold 370 shares of the company's Class A Common Stock. The shares were sold on February 3, 2025, at an average price of $53.31 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback